Free cash flow burn has accelerated to a negative $9.5M in 2026Q2, highlighting the intensifying capital requirements of the firm's current clinical development programs.
| Cash from Operations | -20.08M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M | -288.39K | -42.01K |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -2313.5% | -369.77% | 73.66% | 48.3% | -85.63% | -2437.97% | -586.5% | - |
| Net Income | -27.53M | -12.23M | -2.8M | -7.37M | -14.96M | -8.65M | -480.38K | -78.72K |
| Depreciation & Amortization | 72.77K | 76.87K | 73.36K | 72.45K | 6.04K | 0 | 0 | 0 |
| Stock-Based Compensation | 3.68M | 3.18M | 839.77K | 1.15M | 875.06K | 880.62K | 161.3K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.49M | -276.84K | -1.18K | 65.1K | -227.4K | 144.76K | 161.3K | 110.12K |
| Working Capital Changes | 1.2M | 554.99K | 39.81K | -941.72K | 724.13K | 306.08K | 30.68K | 36.71K |
| Change in Receivables | -889.97K | -362.85K | -13.24K | 118.8K | -45.63K | -110.15K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 279.19M | 85.57M | 810.57K | 2.19M | 5.2M | 26.06M | 1.01M | 122K |
| Debt Issued (Net) | -77.75K | -100.15K | -89.73K | -86.11K | -7.16K | 0 | 0 | 0 |
| Equity Issued (Net) | 280.11M | 86.03M | 900.3K | 1.22M | 4.03M | 27.74M | 1.01M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -839.67K | -360.14K | 0 | 1.06M | 1.17M | -1.69M | 0 | 366K |
| Net Change in Cash | 252.25M | 77.19M | -1.03M | -4.88M | -8.13M | 18.96M | 719.94K | 79.99K |
| Free Cash Flow | -20.08M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M | -288.39K | -42.01K |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | -384.81% | -369.77% | 73.66% | 48.3% | -85.63% | -2437.97% | -586.5% | - |
| FCF per Share | -2.09 | -1.26 | -0.43 | -1.89 | -5.50 | -4.08 | -0.23 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.73x | 0.71x | 0.66x | 0.95x | 0.91x | 0.85x | 0.60x | 0.18x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial execution failure
As reported in recent financial filings, the company's operating cash flow reached a deficit of $9.5M in 2026Q2, highlighting a significant divergence from net income as the firm accelerates its clinical development programs and consumes cash reserves to fund essential research and development activities.
The relationship between net income and operating cash flow remains heavily influenced by non-cash expenses and working capital fluctuations, typical of a pre-revenue biotech entity. Investors should monitor the widening gap between these figures, as it suggests that the company's cash burn is accelerating faster than its accounting losses might imply.
Based on the company's reported figures, free cash flow has deteriorated to a negative $9.5M in 2026Q2, reflecting the intensifying capital requirements of late-stage clinical trials that now dominate the firm's financial profile and necessitate a disciplined approach to managing the remaining cash runway.
The trajectory of free cash flow indicates a clear shift toward higher capital intensity as the company moves through its pipeline milestones. This trend suggests that the firm's reliance on external financing will likely persist until a major value-inflection event or strategic partnership can be secured.
According to quarterly data, working capital changes have fluctuated significantly, including a $1.4M inflow in 2026Q2, which appears to provide a temporary, albeit inconsistent, offset to the company's underlying operational cash burn as it manages its clinical trial vendor obligations and research-related accounts payable.
The erratic nature of working capital movements warrants further investigation, as these shifts often mask the underlying cash requirements of the business. It appears that the company is utilizing payables management to preserve liquidity, a strategy that may offer only limited relief as clinical trial activity scales.
Financial statements reveal that stock-based compensation, which reached $1.3M in 2026Q1, serves as a recurring non-cash expense that effectively masks the true economic cost of talent retention, thereby complicating the assessment of the company's actual cash burn rate relative to its stated research and development objectives.
While stock-based compensation is a standard tool for preserving cash in early-stage biotech, its consistent presence suggests a reliance on equity-linked incentives that may dilute existing shareholders over time. Analysts should adjust for these non-cash charges to better understand the true operational cash requirements of the firm.
Quick answers to the most common questions about buying DRUG stock.
Bright Minds Biosciences Inc. (DRUG) generated $-8.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Bright Minds Biosciences Inc. (DRUG) reported negative free cash flow of $8.7M in 2025, indicating capital requirements exceeded cash from operations.
Bright Minds Biosciences Inc. (DRUG) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.